Summit Therapeutics (SMMT) Other Non-Current Liabilities (2019 - 2026)
Summit Therapeutics' (SMMT) quarterly Other Non-Current Liabilities came in at $1.8 million in Q2 2026, down 1.96% YoY from $1.8 million in Q2 2025, and little changed on a QoQ basis from $1.8 million in Q1 2026.
Summit Therapeutics (SMMT) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 8 years of Other Non-Current Liabilities data on file, last reported at $1.8 million in Q2 2026.
- Quarterly Other Non-Current Liabilities fell 1.96% year-over-year to $1.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 million (down 1.96% YoY) and the FY2025 annual result came in at $1.8 million, up 12.39% from the prior year.
- Other Non-Current Liabilities held at $1.8 million in Q2 2026, from $1.8 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.3 million in Q1 2024 to a low of $1.4 million in Q4 2022.
- A 5-year average of $1.9 million and a median of $1.8 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities sank 48.52% — and 2024, when it soared 123.5%.
- Tracing SMMT's Other Non-Current Liabilities over 5 years: stood at $1.4 million in 2022, then advanced by 9.31% to $1.6 million in 2023, then rose by 4.35% to $1.6 million in 2024, then rose by 12.39% to $1.8 million in 2025, then retreated by 1.64% to $1.8 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.8 million (Q2 2026), $1.8 million (Q1 2026), and $1.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.80 Mn |
| Mar 31, 2026 | 1.80 Mn |
| Dec 31, 2025 | 1.83 Mn |
| Sep 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 3.31 Mn |
| Dec 31, 2023 | 1.56 Mn |
| Sep 30, 2023 | 1.48 Mn |
| Jun 30, 2023 | 1.51 Mn |
| Mar 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | 2.42 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | 2.75 Mn |
| Dec 31, 2021 | 2.78 Mn |
| Sep 30, 2021 | 2.69 Mn |